JOHNSON & JOHNSON insider buying and selling
9 Form 4 filings against JOHNSON & JOHNSON (JNJ) in the last 90 days. Below are the transactions from 4 recent filings, one per insider where the window allows, as filed.
| Date | Insider | Role | Transaction | Code | Shares | Price | Owned after |
|---|---|---|---|---|---|---|---|
| 2026-09-02 | Schmid Timothy | EVP, WW Chair, MedTech | option exercise | M | 11,070 | $131.94 | 36,517 |
| 2026-09-02 | Schmid Timothy | EVP, WW Chair, MedTech | open-market sale | S | 11,070 | $274.74 | 25,447 |
| 2026-09-02 | Schmid Timothy | EVP, WW Chair, MedTech | option exercise | M | 22,527 | $151.41 | 47,974 |
| 2026-09-02 | Schmid Timothy | EVP, WW Chair, MedTech | open-market sale | S | 22,527 | $274.74 | 25,447 |
What the filings show
Across the 4 filings read here, 1 insider at JOHNSON & JOHNSON (JNJ) reported 2 open-market sales of 33,597 shares worth about $9.2M.
The largest by value was Schmid Timothy (EVP, WW Chair, MedTech), with about $9.2M sold on the open market.
9 Form 4 filings were made against JOHNSON & JOHNSON in the 90 days to October 9, 2026; the paid report reads all of them.
The Form 4 flow against JOHNSON & JOHNSON, parsed and explained
The free view above is the newest few filings. The paid report reads the newest Form 4 filings of the last 90 days (up to 100), separates open-market buys and sales from awards, exercises and tax withholding, totals the flow per insider, flags 10b5-1 plans where the filing notes them, and hands you a cited write-up plus a downloadable transactions table.
Generated from public SEC EDGAR filings. Filing data is shown as filed. This is information, not investment advice.